Tag: Strep agalactiae

According to reports, resistance of *Streptococcus agalactiae* to macrolide antibiotics like erythromycin was estimated to be as high as 32% in some areas. This rising trend directly impacts the effectiveness of azithromycin, a related macrolide, as a reliable treatment for *Strep agalactiae* infections.

Recent studies have reported the emergence of multidrug-resistant *Streptococcus agalactiae* strains showing reduced susceptibility to penicillin and cefotaxime. This raises significant concerns regarding the traditional treatment of Group B Streptococcus (GBS) infections, prompting clinicians to re-evaluate whether *Strep agalactiae* is resistant to cefotaxime.

Recent studies have documented the alarmingly high rates of resistance that *Streptococcus agalactiae* (Group B Strep) has developed against tetracycline antibiotics, including doxycycline. This raises a critical question for effective treatment strategies: **Does doxycycline cover strep agalactiae** reliably?